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Implantable Sensors for Heart Failure
CHU-PAK LAU, DAVID CW SIU, HUNG-FAT TSE
From Division of Cardiology, Department of Medicine, The University of Hong Kong, Queen Mary Hospital,
Hong Kong

Why Heart Failure Monitoring

Limitations of Symptoms, Signs and
Investigations

About 5 million Americans suffer from heart
failure, carrying significant morbidity and mortality. It
is estimated that 550,000 new cases occur each year,
and the estimated cost of treatment reaches $33.2 billion,
most of the cost were incurred during hospitalization
for acute decompensation heart failure (ADHF).1
ADHF refers to a clinical condition of worsening
heart failure with dyspnoea and often with evidence of
fluid overload. 2 This is often triggered by one of
the four main factors: atrial fibrillation, anemia,
hypertension and medication/dietary indiscretion.
In the 1991-1994 Connecticut Medicare
beneficiaries review, 3 ADHF that results in
hospitalization carries an 8% in-hospital mortality.
Importantly, of the 17,448 survivors, 44% will be readmitted once, of which 18% were due to recurrent heart
failure. Overall, 24% would die in 6 months after the
first ADHF, and 53% either died or re-admitted over
the same period. Thus prevention of ADHF can have
significant prognostic impact for the patient, in addition
to reducing the cost of heart failure management.
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While dyspnea is the commonest presenting
complaints for hospitalization in ADHF, it occurs
relatively late in relation to hemodynamic and fluid
status changes. Until the era of implantable devices, it
is not possible to evaluate the hemodynamic changes
leading to ADHF. Adamson et al4 implanted a right
ventricular (RV) sensor to measure RV systolic and
diastolic pressure during heart failure exacerbation in
32 patients. They found that at a mean of 4±2 days before
admission, RV systolic pressure started to increase in
9/12 heart failure event. As a group, there was an
increase in RV systolic pressure by 25±4% and heart
rate by 11±2% during ADHF. This study suggests that
pressure changes is the initiating mechanism responsible
for heart failure exacerbation. Likewise, using an
implantable intrathoracic impedance sensor to assess
pulmonary fluid, fluid overloading occurs at 18.3±10.1
days before dyspnea occurred.5 Thus, dyspnea is a late
event and does not allow neither the clinician nor the
patient to have enough time for intervention to avert
hospitalization.
The cardinal physical signs of congestive heart
failure are: a third heart sound, pulmonary crackles,
raised jugular venous pressure and pedal edema.
However, these signs have poor sensitivity to detect heart
failure. In a study6 of 50 patients with raised pulmonary
arterial wedge pressure (PAWP) ≥22 mm Hg, lung
crackles were identified in 19% of patients, and a raised
jugular venous pressure and peripheral edema were
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present in only 50% and 20% of patients respectively.
While a third heart sound was heard in most cases, it
was also detected in those with a low PAWP. The
combination of these signs have a sensitivity of 58%
and specificity of 100% for congestive heart failure.
Physical examination of jugular pressure is difficult and
inaccurate.7
Body weight change is both a complaint or signs
for ADHF. It has been suggested that this is an unreliable
sign as body weight is not only reflective of body fluid,
but may depend on amount of food/fluid intake and other
causes of weight loss or weight gain. In a recent study,8
134 patients with heart failure hospitalization
were compared with a case matched group without
hospitalization. Body weight one week before
hospitalization was associated with increasing risk of
hospitalization (Relative risk: >2-5 lb=2.77; >5-10 lb=
4.46 and 5-10 lb=7.65). It is suggested that monitoring
of body weight remains useful and identifies a high risk
group for intervention.
Radiological evidence of ADHF tends to occur
late. Brain natriuretic peptide (BNP) is proposed to
improve heart failure management. In a randomized
study on the N-terminal BNP to guide heart failure
therapy (TIME-CHF) study,9 499 patients ≥60 years old
with systolic heart failure were randomized. Titration
to achieve a N-terminal BNP level of ≤2 times upper
limit was compared to conventional management
without BNP guidance. There was no difference in the
survival rates free from all cause hospitalization between
BNP-guided versus conventional therapy (41 vs 40%),
and a similar degree of quality of life improvement.
However, the secondary endpoint of heart failure
hospitalization was significantly reduced (72 vs 62%),
and outcomes were better in the 60-75 years old patients
but not in those 75 years or older.
While vigilant monitoring of symptoms and signs
(and BNP levels) are useful, they are not guarantee to
accurately predict ADHF. On the other hand, frequent
monitoring of some of these signs and symptoms, and
the use of external physiological (and implantable) data
are clearly superior to conventional care. In a metaanalysis of both cohort (2,354 patients) and randomized
trials (6,258 patients),10 with 6-12 months of follow up,
there is a significantly lower rate of deaths and

2

hospitalization compared to conventional management.
Taken together, frequent monitoring of
physiological parameters are useful for clinical
management of heart failure. As many patients with LV
dysfunction requires implantable cardiac implantable
electronic devices (CIED) either for arrhythmia prevent
or therapy (ICD), or heart failure treatment (CRT or
CRT-D), this opens the possibility to add implantable
sensors for heart failure monitoring in these devices.
The use of implantable sensors will allow continuous
monitoring of physiological parameters without
intensive manpower. Furthermore, the ability of these
sensors to detect earlier physiological changes before
ADHF may open a window for averting heart failure
hospitalization. They can also measure hemodynamics
at different body positions and on an ambulatory basis,
and may obviate the need of invasive monitoring when
the patient is admitted for heart failure therapy.

Monitoring of Pathophysiological Changes
of Heart Failure
There are three possible pathophysiological areas
for heart failure monitoring: monitoring of electrical
remodeling, mechanical remodeling and neurohormonal
changes that occur with heart failure (Table 1). Electrical
remodeling in either the atrium or ventricle will result
in changes in normal automaticity, conduction
properties, and refractory period and predispose to atrial
fibrillation (AF) and ventricular tachyarrhythmias. The
occurrence of arrhythmias are routinely monitored and
treated by CIED, both by pacing and defibrillation.
Effective refractory period (ERP) can be monitored by
physician activated electrical stimulation through a
programmer.
Intra and inter-chamber conduction timing in
heart failure are important, as they are either a result of,
or the cause of electrical remodeling in heart failure. In
a post mortem series of 34 patients with pre-morbid
serial ECG, progressive PR and QRS duration
prolongation occurred with worsening of heart failure.
Cardiac mass index was significantly correlated
with V1-V6 R-wave amplitude.11 A wide LBBB QRS
complex is associated with ventricular dyssynchrony
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Table 1. Monitoring for heart failure pathophysiology
Electrical remodeling
Atrium
Ventricle
Conduction

Examples
Rate, atrial ERP, atrial fibrillation
Rate, ventricular ERP, ventricular tachyarrhythmias
Atrioventricular node conduction time and capacity, intra- and
inter-atrial conduction, intra- and inter-ventricular conduction

Mechanical remodeling
Atrium
Ventricle
Pressure changes

Examples
Size, function, structure
Size, function, structure
End- diastolic pressure, pulmonary artery pressure (and wedge
pressure), venous pressure

Neurohormonal changes
Sympathovagal invalence
Renina-angiotensina-aldosterona-system

Examples
Heart rate variability
BNP

BNP=B-type natriuretic peptide; ERP=effective refractory period

and impair left ventricular function. Optimal left
side and atrio-ventricular (AV) and cross chamber
sequencing are important for the proper systolic function
of the heart . While relatively simple, these conduction
parameters have not been examined as long term
monitor of cardiac decompensation.
The initiating event of heart failure is most often
systolic left ventricular dysfunction. This will affect the
right and left ventricular size, and their systolic and
diastolic function. There will also be an effect on the
atria. Early recognition of these changes by monitoring
may allow pharmacological or interventional
approaches to reverse the changes before clinical heart
failure develops. This opportunity may already present
itself in a patient already implanted with a device such
as a pacemaker in whom long term monitoring of heart
failure may be possible.
However, the major immediate clinical
consequence of heart failure is acute decompensated
heart failure (ADHF). ADHF arises because of fluid
overload (particularly in the lungs), and monitoring of
pressure and volume status and appropriate therapy can
prevent ADHF.
Finally, many neuro-hormonal changes result
from the compensating mechanisms of heart failure.
While not easily measurable directly, these changes may
be reflected through heart rate variability and electrical
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repolarization such as the QT interval. This will be an
interesting new area for monitoring and as a guide to
therapy.

Sensors for Heart Failure
Sensors for rate adaptation can be classified
according to the technical instrumentation. Table 2
summarizes the sensors that have been used for or
proposed to monitor the events of heart failure. The
paced QRS enables QT duration to be evaluated. In
addition, the QRS width, measured as the ventricular
depolarization gradient, had been proposed as a marker
that is sensitive to catecholamines.12 These sensors have
long been used as surrogate markers of sympathetic level
that increases with exercise, with a view to drive a rate
augmentation. It is uncertain if they are also good
markers of increase sympathetic tone that accompanies
heart failure. These parameters are influenced by pacing
rate, cardio-active medications and electrolytes that
frequently occur in heart failure patients, making them
unlikely to be robust sensors for heart failure. On
the other hand, a high percentage of biventricular
pacing is necessary to deliver a high dose of cardiac
resynchronization therapy (CRT).13 A low percentage
of biventricular pacing may herald worsening of LV
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Table 2. Sensor for monitoring heart failure
Ventricular dysfunction
or its triggers

Sensors
Electrogram

Intra-ventricular impedance
Specialized lead

Parameters
Percentage of pacing
ST segment
AF
Ventricular arrhythmias
LV size and function
PEA to monitor LV function

Hemodynamic changes

Transthoracic impedance
Specialized leads

Pulmonary edema
Minute ventilation
PA pressures
PA wedge pressures
LA pressures

Clinical consequences

Electrogram
Piezoelectric

Paced QRS
Paced QT
Heart Rate variability
Activity level

AF=atrial fibrillation; LA=left atrial; LV=left ventricle; PA=pulmonary artery; PEA=peak endocardial acceleration

function due to failure of adequate CRT, and is a
good marker of heart failure decompensation. AF
and ventricular tachyarrhythmias can either be a
consequence or trigger event of heart failure that could
be easily recognized and treated. Heart rate variability
(HRV) can be measured in a non-pacing dependent
patient, and is a well established prognostic marker of
heart failure. 14 Reduction of heart rate variability
antedates heart failure events. While percentage of
biventricular pacing and HRV are rhythm diagnose
rather than implantable sensors, they provide important
indications of the prevailing heart failure status.
Piezoelectric crystals are used to monitor
body motion. Decrease body activity is an intuitive
consequence of heart failure exacerbation.
Impedance refers to low non-cardiac tissue
stimulating alternating currents injected and recorded
between pacing electrode pairs. When injected
between a RV and LV leads, the lead configuration
will encompass part of the LV, thus allowing intraventricular volumes and contractility to be measured.
When injected between an intra-cardiac lead and the
CIED casing, respiratory parameters such as respiratory
rate and minute ventilation can be monitored, and these

4

parameters are affected by dyspnea that occur in ADHF.
This electrode configuration can also detect pulmonary
fluid status, and may be a marker of pulmonary edema.
More direct measurements are now possible with
pressure sensors instrumented in the RV, pulmonary
artery (PA) or in the left atrium (LA). Worsening heart
failure is associated with decreasing cardiac output,
which the body compensates by increasing tissue
oxygen uptake leading to a widening of arterio-venous
oxygen difference. This is reflected by a reduction in
the mixed venous oxygen saturation, which has
been measured by implantable devices. As central
hemodynamic changes are the precipitating events of
ADHF, pressure sensors that measure LA, PA and RV
pressures, have been studied and developed. Recent
development and clinical applications of some of these
sensors are summarized below.

Activity Monitoring
Kadhiresan et al15 reported the use of externally attached
accelerometers at the chest wall to monitor walking
distance in heart failure patients. Using an acceleration
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threshold of 50 mG, a walking speed of 2 mph
(approximately=2.8 METS) can be detected in a group
of 30 patients. The activity log index so defined was
closely related to the walking distance of these patients,
and was increased when patients were tested during
CRT-on versus CRT-off phase. Similarly, time per day
with physical activity greater than a threshold of
70 steps/minute was detected in an implanted
accelerometer sensor,16 and the activity level trended
similarly to HRV trend during ADHF, and correlates
with the NYHA class at baseline. While a crude index,
activity sensing is a good reflection of general well being
of a heart failure patient. It is a readily available sensor
in most CIEDs, and uses minimal battery energy. In
addition, the absence of activity usually signifies the
patient is at rest, and allows other measurements such
as respiratory parameters to be determined. The use of
accelerometer rather than piezoelectric crystal avoids
some of the external vibration interference on measuring
body activity. An activity sensor is used in conjunction
with other sensors for heart failure monitoring.

Heart Rate Variability
In patients with heart failure, neurohormonal
activity predicts cardiovascular outcome. HRV is an
indirect measure of autonomic tone, and predicts both
sudden and non-sudden cardiac death.17,18 HRV has been
proposed not only to prognosticate heart failure severity,
but also as a guide to treatment and perhaps predict
ADHF.
In a randomized study of 50 patients with an
implanted CRT, 19 HRV was measured in the atrial
sensing mode (VDD at 30 bpm) in either the CRT-on or
CRT-off mode. HRV, measured as the SD of atrial cycle
length of all atrial sensed beats, was significantly higher
in the CRT-on versus the CRT-off arm (25% higher)
and when the patients were receiving betablocker (27%
higher). There was no difference in the level of
catecholamines measured in the study. The authors
concluded that time-domain HRV was improved with
CRT, likely reflecting changes in both sympathetic
and parasympathetic activities with heart failure
improvement.

J HK Coll Cardiol, Vol 19

In the Boston Scientific device, HRV is measured
by the so-called SDANN. SD of the intrinsic intervals
in the 288 five-minute segments of a day is measured,
and averaged over a week. If the percentage of intrinsic
beats is <67% for 24 hours, the data for that day is
discarded. Using the SDANN in a cohort study of 113
heart failure patients with CRT, CRT resulted in a
reduction in the ventricular heart rate, mean heart rate
and an increase in SDANN (from 69±23 ms to
93±27 ms) after three months. Furthermore, lack of
HRV improvement predicts non-responders to CRT.20
The HRV can be plotted at each heart rate over a
twenty four hours period, resulting in a so-called "footprint" in the Boston Scientific CRT devices (Figure 1).21
The normalized size of the foot-print is termed the footprint number, and the graph and number give an easy
understanding of the level of HRV: "the larger the
better". In another cohort study,22 HRV using either the
SDANN or foot-print predicts mortality in 842 patients
implanted with CRT during a 11.8 months follow-up.
A clinical score was derived based on a 2-week post
implant diagnostic data: SDANN <43 ms, mean heart
rate >74/bpm, foot-print number <29 and activity
percent <5% from a 436 patient cohort in the CRT
RENEWAL study.23 Using this scoring system, patients
could be triaged to a low, moderate and high risk group.
When applied to a separate group of CRT recipients in
the HF-HRV cohorts, this scoring system accurately
predicted the level of mortality risk (low 2.8%, moderate
10.1% and high 13.4%) depending on tertiles of their
score.
In the Medtronic device, a long term measure of
HRV, the SD of a 5-minute median AS-AS interval
(SDAAM) is used. The algorithm averages the 24-hour
SD of intrinsic atrial cycle length, and will exclude the
day's data if the percentage of atrial pacing exceed 80%
or an atrial high rate episode (AHRE) are detected. The
change in SDAAM is compared to a rolling average of
the preceding 6 months. The SDAAM, night time heart
rate and activity level were used to predict outcome and
to detect HF hospitalization in a 397 patients cohort.24
A SDAAM <50 ms predicts overall mortality, and the
absolute value of SDAAM remains low in those who
were either hospitalized or died. SDAAM declines from
76±27 ms to 64±26 ms at the time of hospitalization,
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Figure 1. Heart Rate Variability represented by "foot-print". In this patient, improvement of heart failure concurred with an
increase in size of the foot-print after initiation of cardiac resynchronization therapy (CRT).

and the change was apparent up to 3 weeks before the
event. An algorithm was developed to use SDAAM to
predict hospitalization. At a threshold of 200 ms days,
a sensitivity rate of 70% was associated with 2.4 falsepositive events per patient year of follow up, at a median
of 16 days before the event. The sensitivity is not
affected by the use of beta blockade. The SDAAM is
significantly better than the night time heart rate and
activity level change for predicting heart failure. These
date suggest that autonomic surveillance such as the
use of HRV is a good way to monitor both HF prognosis
and to predict ADHF. HRV is limited when these are
high percentage of atrial pacing and during atrial
tachyarrhythmias, and medications may affect HRV
measurements.

Percentage Biventricular Pacing
When CRT is used to treat patients with heart
failure with a widened QRS complex on the ECG, it is
expected that an adequate percentage of biventricular
pacing will be needed to maximize the "dose" of
resynchronization. In a cohort retrospective analysis of
2 heart failure trials involving CRT-D's (1,812 patients),
Koplan et al13 analyzed the relationship between the
percentage of biventricular pacing and the outcome of

6

death and heart failure hospitalization. The mean age
of the patients was 72±11 years, 72% were men and
67% had ischemic cardiomyopathy. When subjects were
divided into quartiles, there was a lower event rate with
an increasing percentage of biventricular pacing. In
particular, there was a 44% reduction in event rates in
those paced 100% of the time versus those paced less
than 92%, and even subjects paced 93-97% had a higher
event rate compared to those paced between 98-99%
(22% higher mortality). The main reason for an
inadequate percentage of pacing was atrial arrhythmias.
Thus a high percentage of biventricular pacing of ≥98%
is an important goal to achieve in patients with CRT
(Figure 2).
A low percentage of biventricular pacing is
particular the problem in those with AF, especially when
permanent. Because of frequent intrinsic conduction and
fusion beats in AF, a high percentage of biventricular
pacing may still not reflect the percentage of true
mechanically synchronized beats. In one study on 19
patients with permanent AF with diagnostic counters
showing >90% biventricular pacing,25 12 lead Holter
System was used to monitor 'true' complete biventricular
capture using a template matching system. Only 9/19
(47%) had adequate complete biventricular pacing, the
remaining had either fusion or pseudo-fusion beats.
Patients with 86.4±17.1% full capture had ≥1 NYHA Class
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improvement than those fully captured at 66.8±19.1% of
the time. This study suggests careful evaluation of the
percentage of biventricular pacing using multiple
surface ECG lead will be needed in those with AF and
conducted response, and sensor to detect full
biventricular capture will be an interesting development.

Right Ventricular Pressure
PA pressure and PAWP monitoring have been
shown to be effective for tailored therapy in patients

admitted with advanced heart failure.26 Early attempts
have been made to continuously record PA pressure on
an ambulatory basis.27,28 An implantable sensor that
measures pressure has been incorporated into a pacing
electrode with an initial application for rate adaptive
pacing. 29 This sensor is a hermetically sealed
piezoelectric crystal with a diaphragm facing the blood
stream. Early experiences have shown the ability to
continuously record RV pressure by connecting this
electrode to an implanted hemodynamic monitor.30,31
The Medtronic Chronicle IHM (Model 9520) is
a non-pacing implantable pulse generator capable of

Figure 2. Optimization of Biventricular pacing. This patient had an initial response to cardiac resynchronization therapy (CRT),
but developed heart failure associated with a reduction of left ventricular pacing to 88%. This was found to be due to frequent
ventricular ectopics interfering with CRT. Prescription of amiodarone suppresses ectopics, and resulted in a 97% biventricular
pacing (and 67% atrial pacing) and significant clinical improvement.
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external radiofrequency connection and integration
in a web-based system. It has a 128 kb of RAM for
continuous storage of sensor data. Piezoelectric activity
from a passively fixed lead in the RV outflow tract is
sampled up to once every 2 seconds, timed to the sensed
unipolar RV electrogram. The sensor frequency is linear
up to 100 Hz, and a 60 Hz high pass filter is used. The
frequency and timing of RV systolic pressure sampling
are programmable, and often at early morning when
the subject is likely to be supine and rested. In addition,
high resolution recording can be made using an external
triggering device. RV pressures (systolic, diastolic and
dp/dt) were recorded, and RVSP reflects PA systolic
pressure. A prior work 32 has assessed the ability to
estimate PA diastolic pressure which occurs at the time
of pulmonic valve opening. This is estimated at the time
of the maximum positive RV dp/dt. Pre-implant
calibration pressure is required to allow absolute
pressure measurement. An external barometric pressure
measurement device provides external pressure
reference against which sensor data can be subtracted.

Feasibility Study
The long term stability of the pressure sensor has
been previously reported. In one study,33 serial SwanGanz catheterizations at 3, 6 and 12 months post implant
showed a small baseline error at 12 months of <1 mm
Hg from the time of implantation. Furthermore, the
accuracy of pressure measured is not affected by body
posture. Adamson et al4 studied 32 patients with heart
failure who received a Chronicle IHM. They found that
long term RV pressure was stable in most patients.
However, in certain subjects, it showed significant
variability despite measurements were taken at 4 am
with no activity level registered. During a total of 36
volume-overloaded events, RV systolic pressure
increased by 25±4%, heart rate by 11±2% and estimated
PA diastolic pressure rose 26±4%. In all events,
pressures were increased one day before the required
clinical intervention. In patients with heart failure
hospitalization, increases in one of the pressures
occurred in 9/12 events, whereas this occurred in
9/24 patients during a non-hospitalized episode. During
a volume depleted state in 7 patients, RV pressure
parameters were reduced. All patients returned to
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baseline levels after therapeutic intervention. The
authors further proposed a sustained increase in one of
the pressures (>20% from baseline) may occur in
patients subsequently admitted, at a mean of 4.2 days
before admission. When the device data were available
to the monitoring physician, a reduction in heart failure
hospitalization was subsequently observed. This
important study also documents the time sequence of
RV pressure changes that occurred before heart failure
exacerbation, suggesting that pressures (and very
possibly also volume) build up may occur for several
days and reduce the patient's "tolerable reserve", before
the final increase in pressures that lead to clinical heart
failure exacerbation. In a further study, Zile et al34
compared the ongoing RV hemodynamics between
systolic and diastolic heart failure patients during heart
failure events. They found RV diastolic pressure to be
elevated in both conditions, although there was a trend
for more rapid RV diastolic pressure elevation to occur
in diastolic heart failure with less compliable ventricle
than during systolic heart failure. Thus quite aside from
monitoring heart failure for intervention, the implantable
pressure device enables an understanding of heart failure
pathophysiology that was not possible before.

Clinical Outcome Study
The COMPASS − HF (Chronicle Offers
Management to Patients with Advanced Signs and
Symptoms of Heart Failure) Study 35 prospectively
randomized 274 NYHA Class III or IV heart failure
patients into conventional care group or therapy
guided in addition by Chronicle derived RV pressure
parameters. The two safety endpoints documented no
pressure sensor failure and 8% implanted system
complications. During a follow up of 6 months, there
was a statistically insignificant trend for reduction of
either heart failure hospitalization or the need of
intravenous diuretics (primary endpoint) by 21%. A
post-hoc analysis showed a 36% prolongation in time
to the final heart failure-related hospitalization in the
Chronicle-guided treatment group.
As suggested by the authors, the lack of
significance observed in the primary efficacy endpoint
may be due to the lower than expected number of heart
failure events (predicted 1.2/6 patient-month; actual
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0.85/6 patient-month), thus decreasing the power of the
study. The lower event rate may be due to enrollment
in highly specialized centres in which there was high
compliance of evidence based heart failure treatment.
Importantly, Chronicle guided therapy resulted in 54%
more adjustment in diuretic doses, without an increase
risk in hypovolemic related heart failure events. At the
time of study, patient transmitted Chronicle data at least
once per week. It is arguable if a more frequent
transmission such as in a remote patient monitoring
system may further contribute to reduction in ADHF.
As mentioned above, the study also includes 70/274
patients with diastolic heart failure patients, A subgroup
analysis36 found a 20% non-significant reduction in
heart failure events when diastolic heart failure patients
were managed occurred with Chronicle-guided
information. This will be of interest in future larger trials
to prevent heart failure in diastolic heart failure which
has few proven therapies.

Other Pressure Sensors
Left Atrial Sensor
PA diastolic pressure is an indirect assessment
of the filling LV pressure, and measurement of LA
pressure may reflect an earlier pressure change that
triggers pulmonary congestion. This may allow a longer
time window for physician intervention to avert ADHF.
The HeartPOD LA pressure monitoring device
(St Jude Medical Inc) comprises an implantable sensor
lead that is attached to a coil antenna for telemetry of
sensor signals. The sensor is a pressure sensor with a
titanium pressure sensing membrane of 3 x 7 mm. It is
capable of high fidelity pressure, temperature and
electrogram measurement. An external patient advisory
module (PAM) sends a 125 KHz radiofrequency
transmission to the antenna, which then captures a 20
second sensor data. The PAM has a 13 Mb of memory,
and can store about 3 months’ data of 6 recordings per
day.
In a feasibility study in a single centre,37 8 patients
received the LA pressure device using a transeptal
approach from the femoral vein. Venous entry at 1 cm
above the inguinal ligament was achieved guided by a
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guide wire introduced in the conventional manner in
the femoral vein below the inguinal ligament. After
standard transeptal puncture, an II F sheath was placed
in the LA, and the sensor was deployed until the distal
set of anchor was on the left side of the atrial system.
The sheath was then removed, and the sensor membrane
was positioned 1-2 mm on the left atrial septum. All
patients received dual antiplatelet therapy for 6 months
(aspirin 160 mg and clopidogrel 75 mg per day). The
device was calibrated overtime using a Valsalva
maneuver technique during which the expiratory
pressure as measured by the PAM will equate to the LA
pressure. Over a period of 6 months, the net drift was
0.2±1.9 mmHg per month, although in 1 patient the drift
was much more. The authors commented on the need
to maintain the sensor orthogonal to the septum to avoid
distortion of LA pressure waveform.
The Hemodynamically Guided Home
Self-Therapy in Severe Heart Failure Patient
(HOMEOSTASIS) trial enrolled 40 patients with Class
III to IV HF.38 All patients received LA pressure device
successfully, although sensor failure occurred in 4
patients, which was subsequently replaced in 3. The
study started after a 3 months run in period in which
heart failure hospitalization and related events, and
medication dosages were documented. Thereafter, LA
pressure data were disclosed to the patients, who in
conjunction with the physician, adjust the dosages of
diuretics. Survival without heart failure events occurred
in 61% at 3 years. Mean daily LA pressure therapy
resulted in a fall of LA pressure (17.6 mmHg to
14.8 mmHg), reduction in elevated LA pressure
frequency (events >25 mmHg by 67%), and better
NYHA Class, LVEF, and more frequent up-titration of
angiotensin converting enzyme inhibitors and reduction
in diuretic dosages. This titration was effected by the
patients themselves using a regimen advised by the
digital assistant machine that interrogate the device on
a daily basis.
The HOMEOSTASIS trial is an interesting
observational study in which LA pressure parameter is
treated similarly to blood glucose parameters in a
diabetic patient, in which self adjustment of dosages of
diuretics may maintain an euvolemic state. Thus the
possibility of reduced clinical events may be due to up-
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titration of angiotensin converting enzyme inhibition
by reducing the dose of diuretics if LA pressure is low.
Conversely, when LA pressure increases, increasing the
dose of diuretics would enable a larger dose of beta
blockers to be given. As a result the target doses of both
drugs were achieved in 54% of patients compared to
only 27% at baseline.
The LA pressure sensor is an interesting concept
and will require to be confirmed in prospective
randomized trials. At present, there remains the issue
of sensor stability, ease of implant (subclavian
implant tools are now available), and the risk of
thromboembolism (which is probably low similar to
occluder for closing atrial septal defect).

Pulmonary Arterial Pressure Sensors
A PA p r e s s u r e t r a n s d u c e r ( C h a m p i o n ,
CardioMENS, Atlanta, GA USA) has been developed.39
The preliminary results of a 550 Class III heart failure
trial has been recently reported. Patients were either
randomized to PA pressure guided therapy versus
conventional care, and a 30% relative risk reduction was
observed. The trial has not reported any significant
safety issues.

Intrathoracic Impedance for Pulmonary
Fluid Status

over every 20 patients is made and averaged. The
moving average of the impedance used to establish a
baseline impedance level against which any change can
be compared. The algorithm is inactive for the first 34
days after device implantation to allow time for postimplant pocket healing and electrode stabilization.
When pulmonary fluid has accumulated beyond a
programmable threshold, an alarm will be used to alert
the patient (or the physician via remote monitoring).
(Figure 3)

Feasibility Studies
The feasibility of using intrathoracic impedance
to monitor fluid status has been tested in 34 patients
with NYHA Class III or IV heart failure in the MIDHeft Study.5 A defibrillation lead in the RV apex is
connected to a special pacemaker capable of injecting
and sourcing impedance. Three impedance current
vectors were tested: RV lead ring to device case and
sampled from coil to device case; RV coil to device
case and sampled from RV coil to device case; RV ring
electrode to device case and sampled from RV tip
electrode to device case. The electrode pairs that use
RV coil to device case has been found to be most
suitable. An initial decrease in impedance followed by
an increase to steady state is observed during pocket
healing, which peaks by about 4 weeks.

Dyspnea is the commonest presenting symptoms
for ADHF, and congestion or edema are the main
underlying mechanisms for dyspnea. Increase in fluid
in the lungs will decrease the transthoracic impedance
which can now be measured with an implantable device.

Device Description
The concept of impedance to monitor pulmonary
congestion is based on a canine experiment by Wang et
al.40 The Medtronic OptivolTM fluid management system
uses transthoracic impedance to measure pulmonary
fluid. Low voltage, non-stimulating currents are injected
between RV ICD electrode (e.g. InSyn Sentry) or RV
bipolar electrode (e.g. Advisa) to the ICD or pacemaker
casing between noon and 5 pm, at a time when the
subject is presumably ambulant and upright. A sampling
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Figure 3. Recurrent heart failure episodes in a patient with
dilated cardiomyopathy, as documented by impedance
recoding of pulmonary fluid index (Medtronic Optivol).
A threshold of 60 Ω. day was found to be unspecific to detect
fluid overload. Fluid index exceeding 100 Ω. day was used
and correctly identified clinical (and BNP confirmed) heart
failure episodes.
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During a follow up of 20±8.4 months, 25
adjudicated heart failure hospitalization occurred in 10
patients. Intrathoracic impedance started to decrease
before worsening symptoms at 15.3±10.6 days, whereas
dyspnea was only reported at the earliest 3 days before
hospitalization. During 17 hospitalizations, pulmonary
capillary wedge pressure was found to significantly
correlated with impedance (r=-0.61, p<0.001), and
impedance increased as fluid removal occurred with
dieresis.
An algorithm for heart failure detection was
derived from 6.2 patient-years of monitoring from 10
patients, and tested in the remaining cohort. Depending
on the set threshold for impedance crossing, a receiver
operator curve was constructed. Lower detection
thresholds lead to higher sensitivity to detect ADHF but
also a higher false positive rate of detection. Conversely,
a higher threshold will be more specific but may underdetect some ADHF events. A 60 Ω. day was suggested
to give a sensitivity of 76.9% at the expense of 1.5 falsepositives per patient-year of monitoring. Early warning
occurred at 13.4±6.2 days of heart failure hospitalization
event. This landmark study shows that intrathoracic
impedance is correlated with pulmonary congestion, and
changes in a predicted way as dieresis occurs, allowing
its use for acute monitoring. Furthermore, the
impedance changes days before ADHF and suggests its
role to monitor heart failure on an ambulatory basis.

Clinical Outcome Studies
The impact of automatic Optivol alert to guide
therapy was observed in 532 heart failure patients in
the Italian Optivol Study.41 With the Optivol heart failure
alert on, a 67% detection of heart failure that required
either hospitalization or therapy adjustment were
detected. Interestingly, of the remaining patients in
whom Optivol alert was inactivated, heart failure
hospitalization was significantly higher (20% vs 7%).
The study also showed a false positive detection rate of
0.5 per patient-year of follow up.
While impedance monitoring from RV coil to
device case monitors lung edema, measurement of RV
and LV lead vectors (for lead integrity) may be able to
assess LV volumes better. In an interesting study on
170 patients, with 43 being replacements, Maines et
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al 42 showed that a 12-week maturation period was
required for the pocket and the leads occurred in the
de-novo implants. However, a similar, albeit stabilizing
earlier, adaptation was still required for replacement
group, suggesting the adaptation is in part due to the
leads or algorithm itself. Interestingly, using the RVLV impedance vectors, this study suggests that there
are significantly difference in impedance measured in
the volume responder versus non-responder groups, with
a higher biventricularly measured impedance in the
responders This suggests the role of impedance to tract
responders to CRT.
The ability of Optivol to reflect heart failure
outcome has been examined in several cohort studies.
In a multi-centre studies of 558 heart failure with In
Sync Sentry from 34 Italian centres, device recorded
Optivol fluid index above 60 Ω. day was associated with
a 36% increased risk heart failure hospitalization over
a 326±216 days of follow up.43 Multivariate analysis
showed that in addition to Optivol level, a higher
percentage of days with low activity, low HRV and
increased night time heart rate were independent
predictions of hospitalization. In 62 patients
with Optivol algorithm, prospective observational
measurements of NT-pro BNP, clinical heart failure
status were collected over 27±2 weeks.44 There was a
significant but weak relationship in all pooled change
in impedance and change in NT-Pro-BNP level over all
the visits (r=0.30, p<0.001). However, NT-Pro-BNP
level increased significantly when an Optivol alert is
associated with clinical signs of ADHF (89±25%
increase) versus an insignificant increase in those
without signs (25% increase). In patients with an alert,
NT-Pro-BNP increase by >10% in most incidents. By
the time of patient medical visit, impedance continued
to fall suggesting worsening heart failure status. In 42%
of cases, a device alert was not related to clinical signs
of heart failure, although BNP on the whole increased
significantly by 25% in these patients. Several
explanations are proposed, including improvement of
medication/dietary compliance by the patients due to
the alert, signs of heart failure may be less sensitive
than objective monitoring, or true false detection by the
Optivol. Nevertheless, the higher BNP level related to
Optivol alert means that heart failure prognosis will be
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affected when Optivol threshold crossing occurred.
The usefulness of Optivol to prevent heart failure
was reported in a single centre case control study in
which 27 patients with Insyn Sentry was compared to
clinically similar group of 27 patients with CRT-D
without Optivol.45 12/27 patients had Optivol alerts,
resulting in intervention. Hospitalization occurred in
only 1/27 over a year of follow up. In contrast, 7/27
patients had heart failure hospitalization in the
controlled patients treated with conventional CRT-D
without the Optivol algorithm. When coupled with
remote patient monitoring (Medtronic Carelink), 20/28
(71%) Optivol alerts in 67 patients can be remotely
managed. 46 The temporal relationship between
arrhythmias and Optivol measured fluid level has been
reported. In one study,47 Optivol threshold crossing
>60 Ω. day was related to a higher risk of occurrence
of AF. AT occurred in 43% before or 29% after Optivol
level crossing. This relationship was not observed in
another study.48 However, the latter study showed a
higher prevalence of VT/VF at lower level of Optivol
15-45 Ω. day, suggest VT/VF occurred at a time of fluid
index crossing. The ability of fluid index to predict
arrhythmias required further study.

Algorithm Considerations
Small et al49 examined in a prospective cohort of
326 patients with InSyn Sentry followed up for nearly
a year. In the first 4 months (observational period),
threshold crossing at the nominal 60 Ω. day occurred
in 17 patients (22 ADHF episodes). The occurrence of
threshold crossing predicted a 35% increase in
hospitalization in the subsequent period. Furthermore,
the following are predictive of hospitalization:
>3 threshold crossing per year or >30 days threshold
crossing per year. When a multivariate analysis was
applied, only night time heart rate remained predictive
of ADHF in addition to Optivol threshold crossing. Thus
not only the threshold crossing but the duration in which
Optivol threshold above the programmed threshold are
predictive of heart failure hospitalization.
The threshold for Optivol alert has also been
tested in 115 patients implanted with Medtronic InSyn
Sentry CRT-D.50 During a follow up of 9±5 months, 45
Optivol alerts occurred in 30 patients. Fifteen alerts
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(33%) were correlated with clinical signs and symptoms
of heart failure, and the authors suggested an increase
of threshold to 90 Ω. day may increase the specificity
to 73%. The authors did not find any causes for false
positive alerts, but patients with heart failure had
significantly higher Optivol level versus those without.
On the other hand, in the European InSyn Sentry
Observational Study on 373 subjects,51 the level of
60 Ω. day was associated with a 60% sensitivity and
60% positive prediction of ADHF. This study
documented 9/53 (17%) events were not associated
with an Optivol alert, and in an additional 11 events, an
increase in Optivol level occurred but did not exceed
the programmed detection threshold. These studies
confirm the usefulness of intrathoracic impedance to
monitor ADHF, but pointed out the need of fine tuning
of detection algorithm and/or individual programming
of Optivol detection level.
The SENSE-HF study is a prospective trial to
assess the sensitivity and positive predictive value of
implantable intrathoracic impedance to predict heart
failure hospitalization.52 The study is of 3 phases. Phase
I is a double blind phase in which retrospective analysis
of Optivol algorithm in predicting ADHF is evaluated.
In Phase II which takes place after 6 months in Phase I,
the device alarm is used to identify ADHF. When this
happens, the patients enter Phase III in which the
utilization of Optivol level is assessed prospectively in
averting ADHF and hospital resource utilization. The
recruitment has been completed in 2008.

Advantages and Limitations
Intrathoracic impedance to monitor heart failure
is one of the most extensively used sensors for
monitoring heart failure. The advantages of this sensor
is the relative ease of instrumentation, requiring no
additional leads or complexity of implantation. The
battery energy expenditure is low. It has been relatively
well characterized in acute setting and for long term
monitoring. While sensitive, its specificity may be
limited as impedance in the vector used may be liable
to be affected by a number of clinical events that do not
indicate pulmonary congestion, such as the occurrence
of pleural effusion (Table 3).53 However, some of the
Optivol alert without clinical evidence of heart failure
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might represent clinical resolution of heart failure due
to delayed presentation, subclinical congestion in
addition to being false positive. Nevertheless, when
combined with other sensors, intrathoracic impedance
is useful for long term and acute monitoring of heart
failure (see below).

between hemodynamically stable ventricular
tachycardia and supraventricular tachycardia.55 These
results suggest that unipolar impedance reflects LV
contractility only when the changes are significantly
gross, and may not be able to detect small changes in
cardiac contractility as in heart failure monitoring.

Multipolar Impedance

Intracardiac Impedance
Impedance signal derived from fully intracardiac
electrodes gives better reflection of volume changes of
the heart than transthoracic impedance. Indeed, Salo et
al54 reported the use of a tripolar RV lead to measure
RV volume changes during cardiac cycle, from which
RV volume and contractility can be derived for rate
adaptive pacing. With the addition of a LV lead in CRT,
more accurate measurement of LV volume is now
possible for heart failure monitoring.

Unipolar Impedance from Right Ventricle
Unipolar impedance injected from the RV apex
to the CIED casing samples a small region in the cardiac
apex. This results in a signal that has been termed closed
loop stimulation (CLS) sensor (see above). As the
majority of the current is lost over a distance of about
1 cm from the apex, the signal reflects regional
contractility of the ventricle rather than reflecting a
change in stroke volume. Likewise, during acute
induction of ventricular fibrillation, the fall in unipolar
RV impedance reflects the fall in arterial pressure.
However, the sensitivity is not enough to discriminate

Table 3. Possible causes of increase in optivol fluid
index in the absence of pulmonary congestions
Mechanism

Examples

Blood viscosity

Anemia

Extra-pulmonary changes

Pleural effusion
Pneumothoracic

Right sided heart failure

Peripheral edema not
detected

Pulmonary changes

Pneumonia
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Several groups and manufacturers have
investigated on the optimal electrode arrangement for
detecting ventricular volumes. With currents flowing
between intracardiac electrodes (RV, LV and RA) and
to the CIED casing, enlargement in ventricular volumes
will decrease impedance as more of the heart is
encompassed. Four intrathoracic and 2 intracardiac
vectors were examined in 16 dogs and 5 sheep. 56
Cardiac function was monitored by biweekly cardiac
catheterization and echocardiography, and LA pressure
by an implantable LA pressure monitor. After several
weeks of high rate pacing to induce heart failure, there
was significant fall in ejection fraction (52 to 34%),
increase in LV end diastolic volume (65 to 97 ml), RV
end diastolic volume (7 to 16 mmHg) and LA pressure
(7 to 26 mmHg). Impedance value measured by all
vectors decreased with the onset of heart failure, with
the maximum decrease occurring with LV-Can and LVRV. Importantly, LV-Can impedance changes more with
heart failure than vectors involving the right heart
electrodes (RA-Can, RV-Can and RV Coil-Can), and
RV-LV and LV-RA changes were intermediate. LA
pressure correlated best with LV-Can impedance (r2=0.
73) than RV-Can (r2=0.43) and RV Coil-Can (r2=0.52).
Circadian variation in impedance also decreased in heart
failure (5±2 to 2±1%). Thus in these animals models,
incorporation of a LV vector significantly improve the
detection of LV volume increase that occurred in heart
failure.
Biventricularly by measured impedance has been
measured using a quadripolar electrode arrangement.57,58
In 9 mini-pigs with pacing induced heart failure, 58
biphasic pulses (15 µs pulse width, 600 µA constant
current amplitude) were injected between the RV ring
and tip electrode, and impedance was sourced using the
LV ring and tip electrode. The impedance signal
(measured as voltage divided by 600 µA current) was
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recorded using a resolution of 8 bits, and the mean
impedance was calculated over the entire cardiac cycle.
"Stroke impedance" was calculated by the difference
between impedance values during systole and diastole.
Systolic impedance was defined as the highest
impedance 50-500 ms after the R-wave, whereas
diastolic impedance was measured by a 20 ms window
within the R-wave. After 20 days of heart failure
induction by rapid pacing in these animals, the increase
in LV end diastolic pressure was found to be
significantly correlated with the end diastolic
impedance, which decreased by 30% (r=-0.81,
p<0.001). End-diastolic volume also trended in the same
direction as the impedance value which decreased by
20%. The corresponding measured intrathoracic
impedance decreased by 8%, which had a poorer
correlation with the end diastolic pressure. The less
striking change of intrathoracic impedance versus
biventricularly measured impedance might be attributed
to countering effect of lead device casing maturation
which did not occur with biventricular impedance, and
the fact that pulmonary fluid collection was relatively
less in the mild heart failure model studied.
These animal experiments suggest that
biventricular impedance can be used to monitor LV size
and pressure changes that occur with heart failure. The
theoretical advantage over transthoracic impedance are
that there will not be significant time lag for lead / pocket
maturation, and no influence of changes in pulmonary
condition such as pleural effusion and pneumonia. As
elevation of LV end diastolic pressure occurs earlier than
pulmonary edema, this sensor can be used to detect
deterioration of early heart failure which has not resulted
in significant pulmonary fluid accumulation, and indeed
used for monitoring LV function. The limitations include
the need of an LV lead (which restricts its use in a CRT
device), dependence on the relative position of RV-LV
leads (only relative changes rather than absolute value
can be detected), and significant diurnal (and possible
postural) changes that need to be accounted for in an
implantable system.

Clinical Studies
An acute study on biventricularly measured
impedance in 14 heart failure patients during
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implantation of CRT devices was reported.59 The authors
also tested the effect of different LV lead locations on
biventricular impedance measurements, changes in
stroke volume were induced with overdrive pacing.
During a study of 20 overdrive pacing episodes and
6 different lead locations, the pooled data showed good
correlation between measured stroke impedance with
stroke volume (r=0.82±0.10) and pulse pressure
(r=0.81±0.16). the authors reported no significant effect
of LV lead positions but the accuracy and signal sizes
tend to be the best in the mid-ventricular region
compared to either the basal and apical regions. There
was one outlier in the study, and lack of lead fixation
was suggested.
At present, there is lack of data on long
term implant. The relative merits and limitations
of intrathoracic and intracardiac impedance are
summarized in Table 4. In patients with a suitable device
(i.e. with an LV lead), it is very likely that a combined
transthoracic and biventricular impedance can be used.

Minute Ventilation
Dual sensor pacemakers encompassing activity
and minute ventilation have been available for rate
adaptive pacing. Heart failure leads to compensatory
hyperventilation especially in the resting state. An expert
system has been tested to examine the combined activity
and minute ventilation (MV) to predict heart failure.60
The algorithm includes:- (1) mean daily resting and MV
during activity; (2) mean daily activity level. A stable
MV and activity level will suggest stable clinical heart
failure, whereas an increase in MV especially at rest
and combined with decrease in activity suggests
deteriorating heart failure. Conversely, a stable MV level
with increase in activity indicates recovery from heart
failure. Nineteen patients with no history of heart failure
receiving TalertTM (Sorin-ELA, Italy), were compared
with 48 patients with Talent CRT with heart failure.
Wide inter-individual and intra-individual variability
occurred, and a fast Fourier transformed data allowed
7-day periodicity to be accounted for. While mean
activity was similar, the resting and activity MV levels
were higher in the CRT group. Overall, it was reported
that the expert system allowed a sensitivity of 88%,
specificity of 94.7%, positive predictive value of 71%
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Table 4. Relative merits of intrathoracic versus biventricular impedance to monitoring pulmonary edema
Heart failure parameters

Intrathoracic impedance
Pulmonary edema

Biventricular impedance
LV volume

Electrode arrangement

RV lead or coil to casing (tripolar)

RV-LV bipoles (Quadripolar)

Lead/casing maturation

Takes up to 1 month

Less

Influence of lung disease

Yes

Less

Influence of lead location

Less

Significant

Circadian & postural effect

Yes

Yes

Sensitivity & specificity

~70% (depends on threshold)

N/A

Applicability

Pacemakers and ICD

CRT-P or CRT-D

Clinical evaluations

Relatively extensive

Limited

and negative predictive value of 98.2% for heart failure.

ST-Segment Shift
ST segment deviation either heralds ischemia or
myocardial injury. Myocardial ischemia requires
medical therapy or revasculariszation, especially in
symptomatic individuals. Myocardial injury, on the
other, is a medical emergency that calls for emergency
reperfusion. Prompt treatment of a myocardial infarction
will significantly reduce mortality. Delay in recognition
by the patient of chest pain due to infarct (and in some
instances silent infarct) is a significant contribution to
delay presentation of myocardial infarction.61 As long
term external ambulatory ECG recording is unlikely to
be practical, intracardiac electrograms have been tested
and proposed to reflect infarct and ischemia in an animal
model.62 When incorporated into a CIED with patient
alert and remote monitoring, ST segment monitoring
becomes a possibility.
The Angel Med Guardian (now under St Jude
Medical) is a single chamber device with a RV apical
lead. An intracardiac electrogram (ICEG) was derived
from RV apex to the device casing. The device records
a 10s ICEG data once every 90s for normal sinus beat
within 50 - 90 bpm. Data are amplified with a gain of
62.5 - 625 times and band passed between 0.25 to 45
Hz, followed by A/D conversion at 200 Hz. ST segment
level is compared to the corresponding PQ segment
level, and a baseline ST segment level is calculated as a
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rolling 24-hour average which are acquired hourly. The
extent of the deviation is normalized by the average
R-wave voltage. The "normalcy" of ST segment
deviation at different heart rates is further tested during
an exercise, as ST shifts tend to occur at different heart
rates in the absence of ischemia. A rate adjusted
spontaneous ST deviation will then be considered as an
ischemic events and an alert will be triggered.
A limited number of devices have been implanted
in humans. 63 During angioplasty with temporary
coronary artery occlusions, ST segment deviations
occurred, with a negative shift during left anterior
descending artery occlusion, and a positive shift in other
arteries. Ten abnormal alerts occurred in 6 patients,
leading to coronary artery interventions. During stress
testing, the ICEG showed much cleaner signal and
bigger shift than the corresponding surface ECG.
Typically a 40% ST depression in ICEG corresponds to
-0.8 mV on the surface ECG. As the ICEG is recorded
at the RV apex closed to the left anterior descending
territory, ischemia in this artery leads to ST depression,
whereas ischemia in other territories results in a
reciprocal ST elevation. Further work will be required
to explore the ability of ST segment sensor to detect
the culprit artery.
The ST segment sensor is an interesting sensor
for ischemia. In addition to ischemic detection, the
relationship of ST deviation and occurrence of
arrhythmia such as ventricular tachycardia may shed
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light on the ischemic cause of arrhythmia. Quite aside
from the logistic implication of ST segment monitoring
[which requires urgent intervention], ST segment
monitor will be possible only for non-pacemaker
dependent patient. The influence of medications,
electrolytes and heart rate on ST segment needs further
evaluation.

Peak Endocardial Acceleration
Peak Endocardial Acceleration (PEA) sensor has
been used for rate adaptation. The PEA signal measures
the closure sound of the mitral valve, and reflects cardiac
contractility. A minimal PEA signal occurs during
optimal AV interval in DDD devices,64 and reflects the
optimal AV interval in most patients. A new CRT-P (The
New LivingTM CHF, Sorin-Ela, Italy) is now available
to monitor heart function and to program AV interval in
CRT device. The PEA is contributed by both the
contractility and LV filling and an index known as PEA
area is derived by measuring the PEA values at different
AV interval scanning at each VV interval. The maximum
PEA area will define the optimal VV and AV interval
for the patient.

In 15 patients implanted with CRT with PEA
sensor, cardiac catheterization with LV dp/dt was
measured with PEA area determined.65 AV interval was
scanned between 60 and 220 ms. The authors found
a responder rate to CRT (defined by 10% increase in
dp/dt) in 75% of patients. Concordance of PEA area versus
dp/dt methods occurred in 8/12 patients. These data are
interesting, although the role of AV interval programming
on the long term is uncertain, and the ability of the sensor
to monitor LV function remains to be tested.

Combined Heart Failure Diagnostics
The PARTNERS HF (Program to Access and
Review Trending Information and Evaluate Correlation
to Symptoms in Patients with Heart Failure) study is an
observational study on the use of diagnostics to predict
heart failure. 66 100 sites in the US prospectively
recruited 694 CRT-D patients and followed them for
11.7+2 months. Table 5 shows the diagnostic data
considered important in an algorithm to predict ADHF.
A positive algorithm was defined as the occurrence of

Table 5. Eight heart failure device diagnostic parameters and algorithms used to predict heart failure in the
COMPASS-HF study
HF device diagnostic parameter

Algorithm

AF duration

AF ≥6 hours on at least 1 day in patients without persistent AF
(7 consecutive days with ≥23 hours AF)

Ventricular rate during AF

AF ≥24 hours and the average ventricular rate during AF ≥90 beats/min on
at least 1 day

Fluid index (OptiVol)

High fluid index on at least 1 day; thresholds included ≥60, ≥80, and
≥100 Ω. day

Patient activity

Mean patient activity <1 hour over 1 week

Night heart rate

Mean night heart time rate >85 beats/min for 7 consecutive days

HRV

HRV <60 ms everyday for 1 week (minimum 5 measured days)

% of biventricular pacing

Ventricular pacing ≤90% for 5 of 7 days

ICD shock for potentially lethal VT/VF ≥1 shocks during the evaluation period
AF=atrial fibrillation; AT/AF=atrial tachycardia/atrial fibrillation; CRT=cardiac resynchronization therapy; HF=heart failure;
HRV=heart rate variability; ICD=implantable cardioverter-defibrillator; VT/VF=ventricular tachycardia/ ventricular fibrillation.
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22/8 variables during a 1-month period that include:
Long AF duration, rapid AF rate, increase Optivol fluid
index, low patient activity, abnormal automonic tone,
or device therapy. A very high Optivol fluid level
(>100) is considered ADHF.
Ninety patients had 141 adjudicated heart failure
events, occurring after 60 days of implantation. A
positive combined diagnostic set predicts a 5.5 fold risk
of hospitalization in the next month, even after adjusting
for the clinical variables. The main diagnostic
parameters are Optivol ≥60 Ω. day, low activity and
HRV. When additional Optivol ≥100 (28% of patients),
it is also predictive of ADHF. Further sub-group analysis
suggests that the specificity of ADHF is improved with
setting a higher level of fluid index, and using more
non-fluid related indices at the expense of loss of
specificity. Interestingly, in patients with a prior history
of heart failure, diagnostic parameters are no longer
predictive. There is an improvement of diagnostic
accuracy if sampling is performed every 15 days versus
less frequently. Whether closer monitoring with the use
of remote web based system can further reduce ADHF
remains to be tested. Using externally measured
parameters such as Weight Monitoring in Heart Failure67
and/or blood pressure (SPAW CHF II), 68 benefit of
monitoring was not observed in the former but occurred
in the later study. In the first study, patients were
recruited right after a heart failure hospitalization. The
authors suggest that the role of diagnostic data in repeat
heart failure hospitalization may be less than inpatients
without prior hospitalization.
The PARTNERS HF is an important study
suggesting the role of combined heart failure diagnostics
to predict ADHF. While the sensitivity and specificity
of the algorithm needs to be tested in prospective
randomized trials, the occurrence of positive diagnostic
criteria are predictive of a group of high risk heart failure
patient. Conversely, the absence of diagnostic alerts
predict a stable heart failure group. This risk stratification
is over and above the conventional clinical risk factors.

Conclusion
Sensors have been introduced to optimize pacing
rate in patients with chronotropic incompetence. The
J HK Coll Cardiol, Vol 19

art has now matured such that sensor driven rate adaptive
pacing is a programmable parameter of almost all
CIEDs. With the increasing use of CIED to treat and
monitor heart failure, sensors have now metaphored to
optimize programming of CRT devices, and to monitor
heart failure progression.
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Andrew Redington
The Multi-Center Experience of Interventional Treatment of Ventricular Septal Defect in China
Zhiwei Zhang
Paediatric Transplantation in Hong Kong
Kin-shing Lun
Ventricular Mechanics in Congenital Heart Disease
Yiu-fai Cheung
To Be Confirmed
Fang Liu

1630-1700

Coffee Break
Visit Exhibits

1700-1830

Free Paper Session
Paediatric Cardiology II
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The Preliminary Study of Ultrasound Evaluation on Animal Experimental Model of Iliac
Artery Stenosis in Youth Rabbits

J Guan, XL Sun

J Guo,1 XJ Ji,1 GS Yu,1 YH Bai,1 XQ Zhai,1 Y Tang,2 P Zhang,2 Y Wang3
Department of Cardiology, 2Department of ultrasonic, The Children's Hospital of Chongqing Medical
University; 3College of Pharmacy of Chongqing Medical University, PR China
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BMP13 on C3H10T1 / 2 Cells to Improve Cardiac Function in Myocardial Infarction
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Effects of ulinastatin on injury of neurons in hippocampus CA1 area
and cardiac dysfunction after cardiopulmonary resuscitation in rabbits

The preventive effect of inhibiting nuclear factor kappa-B activity on
the aorta endothelial cells in rats with high lipid diet

Xiao-Xing Liao, Chun-lin Hu, Xin Li, Hongyan Wei
Emergency Department, The First Affiliated Hospital of Sun Yat-Sen University ,
Guangzhou, China

Xin Li, Xiao-Xing Liao, Chun-lin Hu, Hongyan Wei
Emergency Department, The First Affiliated Hospital of Sun Yat-Sen University ,
Guangzhou, China

Purpose: To investigate whether ulinastatin can reduce the systemic inflammatory
response, improve cardiac dysfunction and reduce injury of neurons in hippocampus CA1
area after ROSC.
Methods: Cardiac ventricular fibrillation was induced by alternating current in 24 New
Zealand rabbits, which were randomly divided into Control and ulinastatin treated group
after ROSC. Dynamic observation of the effects of ulinastatin on the levels of plasma
inflammatory cytokines TNF-α, IL-6, cardiac function including FS, EF and E/A, and
neuron injury in hippocampus CA1 area after ROSC were performed.
Results: Plasma inflammatory cytokines TNF-α and IL-6 in Control group peaked at 8h
after ROSC, the levels were 441.60±169.89 ng/ml and 622.00±111.18 ng/ml respectively
and reduced to 283.33±32.01 ng/ml and 587.00±102.50ng/ml at 16h. The levels of TNF-α
and IL-6 at each time interval in ulinastatin group were significantly lower than the Control
group(P<0.05). At 4h after ROSC, FS, EF and E/A in Control group were 26.20±3.35%,
33.00±2.12% and 1.34±0.12 respectively. EF, E/A in ulinastatin treated group were higher
than the Control group at 4h,8h and 12h after ROSC. FS Values after ROSC 4h, 8h were
higher than the Control group(P<0.05). At 72h after ROSC, the number of dynamic
neurons in CA1 area of Control group was 13.22±0.97, less than the ulinastatin group
16.89±1.45, P=0.003, and the number of apoptotic neurons in hippocampus CA1 area in
Control group was 15.67±1.37, while in ulinastatin group was 13.67±1.03, P=0.019.
Conclusions: Ulinastatin can decrease plasma inflammatory cytokines TNF-α and IL-6,
improve cardiac dysfunction and have protective effects on neurons in hippocampus CA1
area after ROSC in New Zealand rabbits.

Purpose: To examine the effect of pyrrolidine dithiocarbamate (PDTC) on the aorta
endothelial cells in rats with high lipid diet.
Methods: 18 Sprague Dawley rats were randomly divided into three groups: high lipids
group, PDTC and high lipid group(PDTC group) and normal control group. The aortas
were harvested for histomorphometry and transmission electron microscope 12 weeks
after the induction of high plasma lipid. The nuclear factor κB (NF-κB) activity was
measured by use of electrophoretic mobility shift assays (EMSA) in aortas. The levels of
tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6) in serum were measured by
use of radio-immunity and the level of soluble thrombomodulin (sTM) in serum was
measured by use of enzyme linked immunosorbent assay (ELISA).
Results: There was obvious necrosis or apoptosis for aorta endothelial cells in high lipids
group, but this phenomenon was no clear in PDTC group. The level of sTM in the PDTC
group was significantly higher than that of normal control group and was lower than that
of high lipids group (P<0.05). The activity of NF-κB and the levels of IL-6, TNF-α were
evidently higher in high lipids group than normal control group and PDTC group. There
was a positive relation between the NF-κB activity and the levels of TNF-α, IL-6 and
sTM (P<0.05).
Conclusions: These results indicate that PDTC can protect aorta endothelial cells by
inhibiting the activity of NF-£eB and the inflammatory response in rats with high lipid
diet.
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Implantable cardiovertor defibrillator (ICD) in children and young
adults: experience in Hong Kong
TC Yung,1 KS Lun,1 K Fan,2 LC Cheng3
Department of Paediatric Cardiology, Queen Mary Hospital; 2Cardiac Medical Unit,
Grantham Hospital; 3Cardiothoracic Surgical Department, Queen Mary Hospital, Hong Kong
1

XQ Zhai, XJ Ji, GS Yu, YH Bai, et al.
Department of Cardiology, The Children's Hospital of Chongqing Medical University, PR China

Introduction: ICD therapy is increasingly used in children and young adults. The purpose
of this single centre study in Hong Kong is to evaluate the indications, underlying heart
disease, efficacy, outcome and complications involved with ICD therapy in this group of
patients.
Methods and Results: The hospital records of all patients aged ¡Ø30 years who underwent
ICD implantation were reviewed retrospectively. From 1996 to 2010, 11 patients ( mean
age 15.6 years, range 4 years 8 months to 29 years) underwent ICD placement. The ICD
was implanted for aborted cardiac arrest (5), syncope (5) and primary prevention of sudden
cardiac death(1). The underlying cardiac diseases were congenital long QT syndrome(3),
idiopathic ventricular fibrillation (1), hypertrophic cardiomyopathy (3), dilated
cardiomyoapthy(1) and post-operative Tetralogy of Fallot (3). Ten patients had the ICD
system implanted transvenously, and 1 had the ICD lead placed subcutaneously. Two
youngest patients had the generator placed at the abdominal position. The mean followup duration was 4 years 2 months, range 7 months to 14 years. Three patients received
appropriate shocks for ventricular arrhythmias at a mean duration of 6 months after ICD
implant. One patient had anti-tachycardia pacing for fast ventricular tachycardia.
Complications occurred in two patients. They had inappropriate shocks because of sinus
tachycardia and lead fracture in one, and atrial fibrillation in the other. Three patients
required reintervention: generator replacement in two, generator plus ICD lead replacement
in the other. One patient died because of congestive heart failure 9 months after ICD
implant, otherwise there was no ICD or arrhythmia related mortality.
Conclusions: The mid term outcome of ICD therapy for prevention of sudden cardiac
death in children and young adult is good. ICD implant procedure is safe in this age
group.
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Application of Modified Blalock-Taussig Shunts in Infants with Complex
Congenital Heart Malformations and Outcomes of Follow-up
WQ Tan
Children's Hospital of Fudan University, PR China
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Improvement of Left Ventricular Function after Aortic Valve Repair in Pediatric Patients.
Follow-up Study Using the Novel 2D Strain Method
YP Mi
Children's Hospital of Fudan University, PR China

Surgical Strategy and Outcome for Transposition of Great Arteries with Intact Ventricular
Septum
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Left Cardiac Sympathetic Denervation for Catecholaminergic Polymorphic
Ventricular Tachycardia in a Chinese Child
YW Ting,1 YW Cheng,1 TC Yung2
Department of Pediatrics and Adolescent Medicine, Tuen Mun Hospital; 2Department of

1

Pediatric Cardiology, Queen Mary Hospital, Hong Kong
Catecholoaminergic-polymorphic ventricular tachycardia (CPVT) is a rare but potentially
lethal arrhythmia in children and it usually presented as syncope or sudden cardiac death
related to exertion or emotion. The management of CPVT is difficult and beta-blockers are
the cornerstone of therapy. Some patients continue to have syncope or documented exercise
induced ventricular tachycardia despite on maximum dose of beta-blocker. Implantable
cardioverter-defibrillator (ICD) may be necessary for those with recurrent cardiac arrest and
complications of ICD are not uncommon. Few patients with CPVT have been treated
successfully by left cardiac sympathetic denervation (LCSD). We would like to present a
Chinese boy with this rare disease treated successfully by LCSD and the possible mechanisms
of LCSD were also discussed.
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The Early Outcomes of Trans-Right Ventricle Pulmonary Valve Perforation and
Balloon Valveplasty Procedure for Pulmonary Atresia with Intact Ventricular Septum
G Chen, WB Zhang, M Ye, Y Pan, B Jia
Children's Hospital of Fudan University, PR China

J HK Coll Cardiol, Vol 19

April 2011

43

HK COLLEGE OF CARDIOLOGY, NINETEENTH ANNUAL SCIENTIFIC CONGRESS
ABSTRACTS
Abstracts for Poster Session:

P1.

44

P2.

April 2011

J HK Coll Cardiol, Vol 19

